200
Participants
Start Date
June 1, 2022
Primary Completion Date
June 1, 2030
Study Completion Date
May 31, 2036
Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells
"Engineering Claudin6, GPC3, Mesothelin, or AXL targeting CAR combined with/or without IL7/CCL19 and/or scfv against PD1/CTLA4/Lag3 secreting vector into NK cells, which are isolated from patients with advanced ovarian cancer or other cancers with expression of Claudin6, GPC3, Mesothelin, or AXL, and then transfusing them back the patients.~In some cases, the CAR-NK cells will be combined with CBD or NAD to enhance the therapeutic efficacy."
RECRUITING
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou
Second Affiliated Hospital of Guangzhou Medical University
OTHER